Perspective Therapeutics (CATX) Current Deferred Revenue (2024)
Perspective Therapeutics (CATX) posted Current Deferred Revenue of $1.4 million for Q4 2024, little changed sequentially from $1.4 million in Q3 2024.
Perspective Therapeutics (CATX) Current Deferred Revenue (2024) Analysis & Trends
Perspective Therapeutics has reported Current Deferred Revenue for 1 years, with the latest figure at $1.4 million in Q4 2024.
- Quarterly Current Deferred Revenue changed N/A year-over-year to $1.4 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $1.4 million (changed N/A YoY) and the FY2024 annual result came in at $1.4 million, changed N/A from the prior year.
- Current Deferred Revenue held at $1.4 million in Q4 2024 per CATX's latest filing, from $1.4 million in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $1.4 million in Q1 2024 and troughed at $1.4 million in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.49 Bn | 193.88 Bn | 7.27 Bn |
| 2 | Stryker | 127.80 Bn | 124.32 Bn | 4.50 Bn |
| 3 | Medtronic | 118.98 Bn | 109.76 Bn | 6.41 Bn |
| 4 | Boston Scientific | 73.58 Bn | 73.04 Bn | 3.85 Bn |
| 5 | Edwards Lifesciences | 51.93 Bn | 47.68 Bn | 1.35 Bn |
| 6 | Dexcom | 34.34 Bn | 32.39 Bn | 830.00 Mn |
| 7 | GE HealthCare Technologies | 33.76 Bn | 31.66 Bn | 2.18 Bn |
| 8 | Koninklijke Philips | 26.37 Bn | 23.05 Bn | 4.55 Bn |
| 9 | Steris | 23.07 Bn | 22.59 Bn | 684.20 Mn |
| 10 | Perspective Therapeutics | 386.08 Mn | 386.08 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 1.40 Mn |
| Sep 30, 2024 | 1.40 Mn |
| Jun 30, 2024 | 1.40 Mn |
| Mar 31, 2024 | 1.40 Mn |